The DOI matches its Crossref record.
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial
Open accessAbstract
BACKGROUND Approximately 15% of all breast cancers occur in women with a family history of breast cancer, but for whom no causative hereditary gene mutation has been found. Screening guidelines for women with familial risk of breast cancer differ between countries. We did a randomised controlled trial (FaMRIsc) to compare MRI screening with mammography in women with familial risk. METHODS In this multicentre, randomised, controlled trial done in 12 hospitals in the Netherlands, women were eligible to participate if they were aged 30-55 years and had a cumulative lifetime breast cancer risk of at least 20% because of a familial predisposition, but were BRCA1, BRCA2, and TP53 wild-type. Participants who were breast-feeding, pregnant, had a previous breast cancer screen, or had a previous a diagnosis of ductal carcinoma in situ were eligible, but those with a previously diagnosed invasive carcinoma were excluded. Participants were randomly allocated (1:1) to receive either annual MRI and clinical breast examination plus biennial mammography (MRI group) or annual mammography and clinical breast examination (mammography group). Randomisation was done via a web-based system and stratified by centre. Women who did not provide consent for randomisation could give consent for registration if they followed either the mammography group protocol or the MRI group protocol in a joint decision with their physician. Results from the registration group were only used in the analyses stratified by breast density. Primary outcomes were number, size, and nodal status of detected breast cancers. Analyses were done by intention to treat. This trial is registered with the Netherlands Trial Register, number NL2661. FINDINGS Between Jan 1, 2011, and Dec 31, 2017, 1355 women provided consent for randomisation and 231 for registration. 675 of 1355 women were randomly allocated to the MRI group and 680 to the mammography group. 218 of 231 women opting to be in a registration group were in the mammography registration group and 13 were in the MRI registration group. The mean number of screening rounds per woman was 4·3 (SD 1·76). More breast cancers were detected in the MRI group than in the mammography group (40 vs 15; p=0·0017). Invasive cancers (24 in the MRI group and eight in the mammography group) were smaller in the MRI group than in the mammography group (median size 9 mm [5-14] vs 17 mm [13-22]; p=0·010) and less frequently node positive (four [17%] of 24 vs five [63%] of eight; p=0·023). Tumour stages of the cancers detected at incident rounds were significantly earlier in the MRI group (12 [48%] of 25 in the MRI group vs one [7%] of 15 in the mammography group were stage T1a and T1b cancers; one (4%) of 25 in the MRI group and two (13%) of 15 in the mammography group were stage T2 or higher; p=0·035) and node-positive tumours were less frequent (two [11%] of 18 in the MRI group vs five [63%] of eight in the mammography group; p=0·014). All seven tumours stage T2 or higher were in the two highest breast density categories (breast imaging reporting and data system categories C and D; p=0·0077) One patient died from breast cancer during follow-up (mammography registration group). INTERPRETATION MRI screening detected cancers at an earlier stage than mammography. The lower number of late-stage cancers identified in incident rounds might reduce the use of adjuvant chemotherapy and decrease breast cancer-related mortality. However, the advantages of the MRI screening approach might be at the cost of more false-positive results, especially at high breast density. FUNDING Dutch Government ZonMw, Dutch Cancer Society, A Sister's Hope, Pink Ribbon, Stichting Coolsingel, J&T Rijke Stichting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR
Monticciolo, D. L., Newell, M. S., Moy, L., Lee, C. S., & Destounis, S. V. (2023) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2023.04.002 · Cited by 290
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations
Lubinski, J., Kotsopoulos, J., Moller, P., Pal, T., Eisen, A., Peck, L., Karlan, B. Y., Aeilts, A., Eng, C., Bordeleau, L., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6944 · Cited by 82
Abdel-Razeq, H., & Mansour, R. (2026) · World Journal of Oncology · doi:10.14740/wjon2692
Metadata
- Authors
- Saadatmand, S., Geuzinge, H. A., Rutgers, E. J. T., Mann, R. M., de Roy van Zuidewijn, D. B. W., Zonderland, H. M., Tollenaar, R. A. E. M., Lobbes, M. B. I., Ausems, M. G. E. M., van 't Riet, M., Hooning, M. J., Mares-Engelberts, I., Luiten, E. J. T., Heijnsdijk, E. A. M., Verhoef, C., Karssemeijer, N., Oosterwijk, J. C., Obdeijn, I.-M., de Koning, H. J., Tilanus-Linthorst, M. M. A., van Deurzen, C. H., Loo, C. E., Wesseling, J., Schlooz-Vries, M., van der Meij, S., Mesker, W., Keymeulen, K., Contant, C., Madsen, E., Koppert, L. B., Rothbarth, J., Veldhuis, W. B., Witkamp, A. J., Tetteroo, E., de Monye, C., van Rosmalen, M. M., Remmelzwaal, J., Gort, H. B. W., Roi-Antonides, R., Wasser, M. N., & van Druten, E.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 20
- Issue
- 8
- Pages
- 1136-1147
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2949999402
- Cited by
- 176
- References
- 0
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30275-x
- The paper
- Saadatmand, S., Geuzinge, H. A., Rutgers, E. J. T., Mann, R. M., de Roy van Zuidewijn, D. B. W., Zonderland, H. M., Tollenaar, R. A. E. M., Lobbes, M. B. I., Ausems, M. G. E. M., van 't Riet, M., Hooning, M. J., Mares-Engelberts, I., Luiten, E. J. T., Heijnsdijk, E. A. M., Verhoef, C., Karssemeijer, N., Oosterwijk, J. C., Obdeijn, I.-M., de Koning, H. J., . . . van Druten, E. (2019). MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30275-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.